{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:01:51Z","timestamp":1791997311542,"version":"4.4.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"crossref","award":["EY01792"],"award-info":[{"award-number":["EY01792"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To investigate the potential utility of intravitreal antivascular endothelial growth factor (anti-VEGF) therapy for stages 3 and 4 proliferative sickle cell retinopathy (PSR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Retrospective review of anatomical and visual acuity outcomes after intravitreal anti-VEGF therapy for stages 3 and 4 PSR eyes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      There were 45 PSR eyes (17 stage 3 and 28 stage 4) treated with anti-VEGF agents (bevacizumab (37 eyes), aflibercept (6 eyes), ranibizumab (3 eyes), one eye received both bevacizumab and aflibercept). Follow-up ranged from 1 to 120 months (mean = 21 months). Within 1 month after anti-VEGF treatment, VA improved \u22652 lines in 18\/45 eyes, remained stable in 26\/45 eyes, and worsened in 1\/45 eyes. The median visual acuity remained 20\/20 for stage 3 and improved from 20\/200 to 20\/30 for stage 4 PSR eyes. More stage 4 PSR eyes had VA improvement posttreatment than stage 3 PSR eyes (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003). There were no cases of endophthalmitis. Visual acuity outcomes were similar for anti-VEGF with and without laser treatment. Control of PSR was achieved in 42\/45 (93%) of eyes without the need for pars plana vitrectomy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Within one month of treatment, administration of anti-VEGF therapy of PSR eyes resulted in seafan regression, clearing of vitreous hemorrhage, and stable or improved vision in most eyes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004658","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T21:00:42Z","timestamp":1756933242000},"page":"171-178","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR STAGES 3 AND 4 PROLIFERATIVE SICKLE CELL RETINOPATHY RESULTS IN IMPROVED ANATOMICAL AND VISUAL OUTCOMES"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7791-6998","authenticated-orcid":false,"given":"Jennifer I.","family":"Lim","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University of Illinois at Chicago and Illinois Eye and Ear Infirmary, Chicago, Illinois;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ogugua N.","family":"Okonkwo","sequence":"additional","affiliation":[{"name":"Eye Foundation Hospital and Eye Foundation Retina Institute, Lagos, Nigeria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally S.","family":"Ong","sequence":"additional","affiliation":[{"name":"Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina;"},{"name":"Wake Forest University School of Medicine, Winston-Salem, North Carolina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl D.","family":"Regillo","sequence":"additional","affiliation":[{"name":"Wills Eye Hospital, Thomas Jefferson University Sidney Kimmel Medical College, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne W.","family":"Scott","sequence":"additional","affiliation":[{"name":"Johns Hopkins Hospital, Johns Hopkins University School of Medicine, and The Wilmer Eye Institute, Baltimore, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[{"name":"Retina Consultants of Texas, Houston, Texas; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Cao","sequence":"additional","affiliation":[{"name":"Retina Consultants of Texas, Houston, Texas; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Chen","sequence":"additional","affiliation":[{"name":"Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette A.","family":"Miao","sequence":"additional","affiliation":[{"name":"University of Chicago Pritzker School of Medicine and University of Chicago Medical Scientist Training Program, Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Momenaei","sequence":"additional","affiliation":[{"name":"Wills Eye Hospital, Thomas Jefferson University Sidney Kimmel Medical College, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyou","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Illinois at Chicago and Illinois Eye and Ear Infirmary, Chicago, Illinois;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20251218","first-page":"OP409","article-title":"Retinal neovascularization in sickle cell retinopathy","volume":"83","author":"Goldberg","year":"1977","journal-title":"Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol"},{"key":"R2-20251218","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1001\/archopht.1971.00990050430006","article-title":"Natural history of untreated proliferative sickle retinopathy","volume":"85","author":"Goldberg","year":"1971","journal-title":"Arch Ophthalmol"},{"key":"R3-20251218","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.ophtha.2005.05.026","article-title":"Incidence and natural history of proliferative sickle cell retinopathy: observations from a cohort study","volume":"112","author":"Downes","year":"2005","journal-title":"Ophthalmology"},{"key":"R4-20251218","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/archopht.1991.01080030065040","article-title":"A randomized clinical trial of scatter photocoagulation of proliferative sickle cell retinopathy","volume":"109","author":"Farber","year":"1991","journal-title":"Arch Ophthalmol"},{"issue":"(Pt 2)","key":"R5-20251218","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/eye.1991.41","article-title":"An update on techniques of photocoagulation treatment of proliferative sickle cell retinopathy","volume":"5","author":"Jampol","year":"1991","journal-title":"Eye (Lond)"},{"key":"R6-20251218","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/archopht.1982.01030030593008","article-title":"An update on vitrectomy surgery and retinal detachment repair in sickle cell disease","volume":"100","author":"Jampol","year":"1982","journal-title":"Arch Ophthalmol"},{"key":"R7-20251218","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/eye.2008.296","article-title":"Vitreoretinal management of the complications of sickle cell retinopathy by observation or pars plana vitrectomy","volume":"23","author":"Williamson","year":"2009","journal-title":"Eye (Lond)"},{"key":"R8-20251218","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41433-018-0127-y","article-title":"A comparison of 23-gauge and 20-gauge vitrectomy for proliferative sickle cell retinopathy - clinical outcomes and surgical management","volume":"32","author":"Ho","year":"2018","journal-title":"Eye (Lond)"},{"key":"R9-20251218","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ajo.2013.12.019","article-title":"Vitreoretinal management and surgical outcomes in proliferative sickle retinopathy: a case series","volume":"157","author":"Chen","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R10-20251218","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.oret.2024.01.023","article-title":"Proliferative sickle cell retinopathy: outcomes of vitreoretinal surgery","volume":"8","author":"Rohowetz","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"R11-20251218","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1600-0420.2006.00779.x","article-title":"Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy","volume":"84","author":"Siqueira","year":"2006","journal-title":"Acta Ophthalmol Scand"},{"key":"R12-20251218","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4103\/0301-4738.40380","article-title":"Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy","volume":"56","author":"Shaikh","year":"2008","journal-title":"Indian J Ophthalmol"},{"key":"R13-20251218","doi-asserted-by":"crossref","first-page":"bcr11.2009.2441","DOI":"10.1136\/bcr.11.2009.2441","article-title":"Intravitreal bevacizumab (Avastin) associated with secondary hyphaema in a case of proliferative sickle cell retinopathy","volume":"2010","author":"Babalola","year":"2010","journal-title":"BMJ Case Rep"},{"key":"R14-20251218","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/ICB.0b013e3182845d31","article-title":"Bevacizumab presurgical treatment for proliferative sickle-cell retinopathy-related retinal detachment","volume":"7","author":"Moshiri","year":"2013","journal-title":"Retin Cases Brief Rep"},{"key":"R15-20251218","first-page":"682583","article-title":"Intravitreal ranibizumab for stage IV proliferative sickle cell retinopathy: a first case report","volume":"2014","author":"Mitropoulos","year":"2014","journal-title":"Case Rep Ophthalmol Med"},{"key":"R16-20251218","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1177\/11206721231199273","article-title":"Visual outcome of treating proliferative sickle cell retinopathy in 108 eyes","volume":"34","author":"Okonkwo","year":"2024","journal-title":"Eur J Ophthalmol"},{"key":"R17-20251218","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/2474126417738627","article-title":"Intravitreal bevacizumab for proliferative sickle retinopathy: a case series","volume":"2","author":"Cai","year":"2017","journal-title":"J VitreoRetinal Dis"},{"key":"R18-20251218","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/bjo.83.7.838","article-title":"Angiogenic factors in human proliferative sickle cell retinopathy","volume":"83","author":"Cao","year":"1999","journal-title":"Br J Ophthalmol"},{"key":"R19-20251218","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/bjo.2004.058164","article-title":"The angiopoietin\/Tie-2 system in proliferative sickle retinopathy: relation to vascular endothelial growth factor, its soluble receptor Flt-1 and von Willebrand factor, and to the effects of laser treatment","volume":"89","author":"Mohan","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R20-20251218","doi-asserted-by":"crossref","first-page":"6739","DOI":"10.1167\/iovs.16-19513","article-title":"Expression pattern of HIF-1\u03b1 and VEGF supports circumferential application of scatter laser for proliferative sickle retinopathy","volume":"57","author":"Rodrigues","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R21-20251218","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1001\/jama.2020.23027","article-title":"Effect of intravitreous aflibercept vs vitrectomy with panretinal photocoagulation on visual acuity in patients with vitreous hemorrhage from proliferative diabetic retinopathy: a randomized clinical trial","volume":"324","author":"Antoszyk","year":"2020","journal-title":"JAMA"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004658","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:00:11Z","timestamp":1766073611000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004658","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}